

[Open Peer Review on Qeios](#)

# Recent Trends in Dry Eye Disease Treatment in Asia

Atsushi Kawahara

**Funding:** No specific funding was received for this work.

**Potential competing interests:** No potential competing interests to declare.

## Abstract

**Purpose of review.** Summarize recent trends in the treatment of dry eye disease (DED) in Asia.

**Recent findings.** In recent years, effective new generation eye drops, such as diclofenac ophthalmic solution and rebamipide ophthalmic solution, which are mucin secretion stimulants, and cyclosporine ophthalmic solution, an immunosuppressive agent, have been approved in various countries for the treatment of DED. Additional newer adjunctive therapies such as laser acupuncture as an adjunctive therapy when eye drops do not provide satisfactory results, new generation intense pulsed light therapy and lid debris debridement for meibomian gland dysfunction-related DED, and human umbilical cord serum eye drops for severe DED are also of interest. These adjunctive therapies target the suppression of inflammation primarily.

**Summary.** New generation eye drops have made it possible to control mild DED. For patients with moderate to severe disease, the addition of eye drops and adjunctive treatment is recommended. Because DED with an unstable tear film is common in Asia, treatment of DED in Asia might first include mucin secretion-promoting eye drops, with anti-inflammatory treatment preferred if additional treatment is needed. In addition, further research is needed to improve treatment continuity because DED is a chronic disease requiring continuous treatment.

**Atsushi Kawahara**\*

*Yoshida Eye Hospital, Hakodate, Japan*

\*Author to whom correspondence should be addressed.

**Keywords:** Dry eye disease (DED); Asia; Tear film; Diquafosol; Rebamipide; Cyclosporine; Laser acupuncture; Intense pulsed light; Lid debris debridement; Human umbilical cord serum.

## 1. Introduction

The first choice for dry eye disease (DED) treatment is treatment with eye drops. Until now, artificial tears replacement

has been the primary treatment, but because artificial tears have a short residence time on the ocular surface, the efficacy of artificial tears is limited to temporary improvement of uncomfortable symptoms and blurred vision. Corticosteroid eye drops have also been used, but their side effects, such as increased intraocular pressure and cataracts, make them unsuitable for the long-term treatment of DED, a chronic disease. No evidence has been established that nonsteroidal anti-inflammatory drug eye drops are effective for tear film stability, and there is concern about the side effect of decreased corneal perception. Therefore, sodium hyaluronate ophthalmic solution, which improves subjective symptoms and corneal damage, and does not cause serious adverse events, became widely used. Sodium hyaluronate binds to fibronectin and improves corneal conjunctival epithelial disorders by promoting epithelial cell adhesion and extension through its action <sup>[1][2]</sup>, and also exhibits water retention properties by retaining water molecules within its molecules <sup>[3]</sup>. However, the effect on tear film stability was minor, and in a few cases, there was no improvement in subjective symptoms or objective findings. Although oral hyaluronic acid, which has anti-inflammatory <sup>[4]</sup> and moisturizing <sup>[5]</sup> effects, has been shown to be effective in the treatment of DED when combined with sodium hyaluronate ophthalmic solution <sup>[6]</sup>, it is still desirable that the eye drops alone can control DED.

In Asia, the short tear film breakup time-type DED, accompanied by tear film instability, is common <sup>[7]</sup>. The Asia Dry Eye Society has established the following diagnostic criteria for dry eye in Asia: Dry eye is a multifactorial disease characterized by unstable tear film causing a variety of symptoms and/or visual impairment, potentially accompanied by ocular surface damage <sup>[8]</sup>. This indicates the importance of tear film stability in the treatment of DED. New generation of eye drops and new adjunctive therapies to enhance tear film stability have been reported. The purpose of this study is to evaluate recent eye drops and adjunctive therapies for the treatment of DED in Asia.

## 2. Major Therapy (New Generation Eye Drops)

Up to now, artificial tears have been the first choice of treatment for DED. Artificial tears can replenish normal human tear fluid that cannot be replicated by other eye drops. In addition, most of them are classified as medical devices or drugs that can be purchased over the counter, rather than prescription drugs. As a result, they have become widely available and are still in use today. A wide variety of artificial tears have been developed and are still improving <sup>[9][10]</sup>, but unfortunately, their effects are temporary. The new generation of eye drops is attracting attention. Table 1 summarizes the new generation eye drops for DED treatment in Asia.

Generic name	Main pharmacological action	Recommended frequency of instillation per day	Brand name
Diquafosol	Mucin and aqueous secretion promotion	6 3*	Diquas Diquas LX*
Rebamipide	Mucin secretion promotion	4	Mucosta
Cyclosporine	Immune suppression	1 2	Ikervis Restasis

**Table 1.** New generation eye drops for dry eye disease (DED) treatment in Asia

\*Long-acting diquafosol

### 2.1. Diquafosol

Diquafosol is a dinucleotide derivative that acts on the P2Y<sub>2</sub> receptor [11]. P2Y<sub>2</sub> receptors are expressed in the conjunctival epithelium, corneal epithelium, lacrimal gland secretory epithelium, accessory lacrimal gland secretory epithelium, and meibomian gland secretory epithelium [12]. Activation of P2Y<sub>2</sub> receptors promotes mucin and water secretion on the ocular surface via Ca<sup>2+</sup> and Cl<sup>-</sup> channels [13][14][15][16][17] and thickens the lipid layer in the tear fluid [18][19]. Lacrimal fluid secretion was found to increase for 5 to 30 minutes after instillation [15], and this increase is not related to lacrimal gland function [20]. The fact [15] that the duration of lachrymal fluid increase with artificial tears is only 5 minutes after instillation also supports the lachrymal volume-increasing effect of diquafosol. Diquafosol has also been reported to increase the tear film lipid layer for up to 60 minutes [21]. Diquafosol stabilizes tear fluid by increasing tear fluid volume and increasing mucin and lipids in the tear fluid. On the other hand, diquafosol is thought to promote epithelial cell proliferation and repair by promoting the phosphorylation of epidermal growth factor receptors and extracellular signal-regulated kinases [22]. In fact, diquafosol has been shown to reverse the apoptosis of corneal epithelial cells [23]. In a multicenter clinical trial [24], diquafosol ophthalmic solution improved tear secretion and corneal epithelial barrier function and significantly reduced corneal epithelial damage. This study showed that it was effective not only for the short tear film breakup time-type DED, but also for the tear fluid deficiency-type DED [24]. Diquafosol ophthalmic solution has also been reported to improve not only subjective symptoms of DED (dryness, foreign body sensation, eye pain, photophobia, and blurred vision), but also practical vision [25]. The most frequent side effect of Diquafosol is eye irritation, reported in up to 12.5% [26], but most are mild and no other problematic adverse events have been observed. Thus, although diquafosol ophthalmic solution is a new generation of eyedrops useful in the treatment of DED, the frequent administration, six times a day, has hindered the continuity of treatment [27]. Therefore, the long-acting diquafosol ophthalmic solution was

developed, and approved in Japan in 2022. In this ophthalmic solution, polyvinylpyrrolidone is added to the conventional diquafosol ophthalmic solution to prolong the effect of the ophthalmic solution [28]. The recommended administration is three times a day, and the efficacy and safety of this ophthalmic solution have been shown to be equivalent to those of conventional ophthalmic solutions [28]. Further clinical trials are expected to be conducted.

## 2.2. Rebamipide

Rebamipide, which is a quinolinone derivative, has been approved and widely used for the treatment of gastritis and gastric ulcers through its mechanism of increasing mucin in the gastric mucosa. Focusing on this mucin-increasing effect, it was studied in an animal model of ocular mucin depletion and reported that rebamipide increased the number of mucin-producing conjunctival goblet cells, increased corneal and conjunctival mucin, and improved corneal conjunctival epithelial damage [29]. When human corneal epithelial cells were cultured with rebamipide, it was observed that mucin-like glycoproteins were produced and mucins 1, mucins 4, and mucins 16 were expressed [30][31]. Furthermore, in corneal epithelial wounding models, the epithelium also promotes microvillus recovery during epithelial repair, leading to early restoration of tight junctions between epithelial cells [32]. These results indicate that rebamipide ophthalmic solution improves tear film stability and ocular surface conditions by secreting mucin-like substances [33]. In fact, long-term administration of rebamipide has been reported to increase the stability of the tear film on the cornea and improve corneal epithelial damage [34]. Topical therapy also improves subjective symptoms of DED [33]. The most frequent side effect of rebamipide is dysgeusia (bitter taste), which was reported to occur in 15.7% [35] and 9.7% [29] of patients, and there have been cases involving the development of dacryocystitis, but all were mild and no other serious adverse events were observed. Rebamipide ophthalmic solution is effective in the treatment of DED, and its mechanism of action suggests that it may be particularly effective in patients with keratoconjunctival epithelial damage. Therefore, it is also recommended for the treatment of perioperative DED in ophthalmic surgery [36].

## 2.3. Cyclosporine

Inflammation is one of the causes of DED and also one of the pathologies caused by DED [8][37]. Animal studies have confirmed that dry stress induces the release of T helper 1-type cytokines on the ocular surface and disrupts the corneal epithelial barrier associated with T helper 17 cells [38][39]. Proinflammatory cytokines are increased in the tear fluid of DED patients [40], and inflammation decreases mucin production and secretion in the corneal conjunctival epithelium [41][42], destabilizing the tear film. Therefore, it is necessary to control inflammation and improve the unstable tear film.

Cyclosporine ophthalmic solution, an immunosuppressive agent used to control inflammation, is known to be an effective treatment for DED [43]. Normal tear fluid contains anti-inflammatory factors such as transforming growth factor- $\beta$  secreted by the lacrimal gland and conjunctival goblet cells, and cyclosporin increases transforming growth factor- $\beta$  levels [44].

Cyclosporine also decreases lymphocyte infiltration in the lacrimal glands and conjunctival tissue and inhibits the expression of inflammatory factors [45]. Treatment of patients with mild DED with cyclosporin has been shown to reduce tissue damage due to inflammation [46]. In particular, it is great advantageous that Ikervis<sup>®</sup> can be effective with only one instillation per day. Also, it was reported that there were no findings to suggest the systemic absorption of cyclosporin after

instillation [47]. In view of the above, the new generation ciclosporin ophthalmic solution is an effective option for the treatment of DED. However, inflammation in the short tear film breakup time-type DED, which is more common in Asia, is not considered to be the core of DED treatment in Asia because it is a secondary pathology [8]. Therefore, it has been suggested that ciclosporin should not be administered alone, but that in combination with a mucin secretagogue it can be an effective treatment method [48]. In addition, heat and stinging pain at the time of ophthalmic instillation are recognized as side effects of ciclosporine, and although minor, are considered to be a future issue.

### 3. Adjunctive Therapy

Currently, the primary adjunctive therapy for DED is punctal occlusion. The goal of treatment is to occlude the patient's lacrimal duct, allowing tear fluid to accumulate on the ocular surface. While this treatment improves tear film stability [49][50] and thus is a useful adjunctive therapy, the side effects of plug discomfort and lacrimation are unavoidable [50][51][52]. Newer adjunctive therapies are therefore attracting attention.

#### 3.1. Laser Acupuncture

Acupuncture has been reported to be effective in the treatment of DED [53][54]. Acupuncture modulates the autonomic and immune systems by dilating blood vessels and increasing neuropeptides [55], which in turn regulate the autonomic nervous system and immune system [56][57][58]. In DED treatment, the instability of the tear film is improved by increasing tear protein secretion, modulating hormone levels and lacrimal gland metabolism, increasing the acetylcholine content of the lacrimal gland, modulating vasoactive intestinal peptides, and reducing inflammatory cytokines on the ocular surface [59][60]. Laser acupuncture combines the pathway and acupuncture point theory of Chinese medicine with modern laser technology. This technology is short, painless, sterile, and noninvasive because it uses low-intensity, nonthermal laser irradiation to stimulate acupuncture points rather than metal needles [61][62]. The complications of conventional needle acupuncture (fainting, folding, bending, and stuck needles) are also avoided. Therefore, from the viewpoints of efficacy and safety, laser acupuncture has been suggested to be a useful complementary therapy when eye drop therapy is inadequate [59]. However, laser acupuncture still requires much optimization and adjustment in terms of treatment parameters and laser device design, and the mechanisms of laser acupuncture need to be further explored.

#### 3.2. Intense Pulsed Light

Intense pulsed light therapy was initially used in the cosmetics industry and for dermatological conditions (hypertrichosis, benign cavernous hemangiomas, venous malformations, telangiectasias, pigmented lesions, etc.) [63][64][65][66]. Intense pulsed light devices provide selective heat delivery to specific structures with xenon flashlamps that emit intense multicolor light ranging from the visible to infrared spectrum by adjusting wavelength, penetration depth, and target site [67][68]. The improvement in DED when patients with facial rosacea underwent intense pulsed light therapy suggested that it might be applicable to the treatment of meibomian gland dysfunction [69], and subsequent studies have confirmed that intense pulsed light therapy is an effective treatment for DED associated with meibomian gland

dysfunction [70][71][72][73][74][75][76]. Light energy from the intense pulsed light is absorbed by chromophores and converted to thermal energy, which coagulates superficial blood vessels and eliminates the lid margin telangiectasia, thereby reducing ocular surface inflammation [77]. These responses have been shown to reduce inflammatory markers in the tear fluid of patients with meibomian gland dysfunction-related DED [72]. In these regards, intense pulsed light therapy is a useful adjunctive therapy for meibomian gland dysfunction-related DED. However, conventional intense pulsed light devices offer few variations in energetic and pulse intensity, making it difficult to treat meibomian gland dysfunction according to its severity. In addition, the thermal effect of intense pulsed light therapy may cause bruising to develop on the skin around the patient's eyes. The new-generation intense pulsed light devices have been improved, eliminating these shortcomings and increasing efficacy and safety [78].

### 3.3. Lid Debris Debridement

Lid debris debridement is a treatment to remove bacterial biofilm that have accumulated at the eyelid margin and scurf from eyelashes, and is treated with the BlephEx system (RySurg, Fort Worth, FL, USA) [79]. This treatment was developed from the concept that bacterial biofilms are the cause of meibomian gland dysfunction [80]. *Staphylococcus epidermidis* and *aureus*, which form the bacterial flora of the conjunctival sac and eyelid margin, produce biofilms, which accumulate over the years [81]. When it exceeds a certain amount, quorum-sensing genes are activated [82], toxins and virulence factors that attack host tissues are produced, and the biofilm expands further, causing a vicious cycle [83][84]. The concept that this inflammation causes meibomian gland dysfunction and meibomian gland dysfunction-related DED has made it the treatment of choice for the prevention of their development and exacerbation. In addition, it has recently been reported that meibomian gland expression in combination with lid debris debridement can further improve meibomian gland dysfunction-related DED [85]. The combination of meibomian gland expression considerably releases the obstruction of meibomian gland ducts and reduces the amount of lipase produced by bacteria present in the eyelid, thereby improving the meibum characteristic and normalizing the lipid layer of the tear film. Lid debris debridement is thus a useful adjunctive therapy, but the current situation requires regular treatment, and the number of sessions and duration are not clear.

### 3.4. Human Umbilical Cord Serum Eye Drops

Autologous serum ophthalmic solutions have been reported to be effective in the treatment of severe dry eye, recurrent corneal erosion, graft-versus-host disease, and so on [86][87][88][89][90]. Autologous serum contains growth factors such as epidermal growth factor, acidic and basic fibroblast growth factor, platelet-derived growth factor, hepatocyte growth factor, vitamin A, transforming growth factor, substance P, insulin growth factor, nerve growth factor, fibronectin and serum anti-protein enzyme [91]. These growth factors ameliorate corneal epithelial damage by promoting proliferation, differentiation, and maturation of the surface epithelium. They also cause anti-inflammatory effects. Human umbilical cord serum is thought to have a more potent therapeutic effect than autologous serum due to its higher concentration of growth factors, and is applicable to Stevens-Johnson syndrome and ocular chemical injury, in addition to the aforementioned diseases that benefit from autologous serum ophthalmic solutions [91][92][93][94][95][96][97][98]. However, there are reports [99][100] that

corneal epithelial damage was not significantly improved by autologous serum eye drops, so there may be a question mark over their ability to improve epithelial damage. In light of the above, human umbilical cord serum appears to be a safe and effective adjunct in severe DED, primarily due to its potent anti-inflammatory properties. The challenges of this treatment are that cord blood collection is a complex process that can only be created in facilities equipped with obstetric services and microbiological evaluation with strict preservation protocols, the risk of allergy and the possibility of parenteral infection must always be considered, and cord blood treatment has legal and ethical concerns. There are also legal and ethical concerns associated with cord blood therapy. However, depending on the patient's medical condition, the benefits of the therapy may outweigh the limitations and routine use can be recommended.

#### 4. Conclusions and Future Perspectives

Reports indicate that new generation DED therapies are more effective than artificial tears and sodium hyaluronate, and that mild DED is now controllable. In Asia, where the short tear film breakup time-type DED is more common, the goal of treatment is to stabilize the tear film, so the first option is to administer mucin-secreting ophthalmic solutions. Although there is some controversy over the use of diclofenac versus rebamipide, the mechanism of action suggests that diclofenac may be better for DED, which is primarily a tear disorder, and rebamipide for DED, which is primarily an epithelial disorder. Moderate to severe DED that cannot be controlled with mucin secretagogues is preferably addressed by the addition of anti-inflammatory therapy. Cyclosporine ophthalmic solution and the adjunctive therapies presented in this study are recommended.

Because DED is a chronic disease, an important issue for future DED treatment is improving treatment adherence. It has been reported that only about 10% of DED patients are on instillation as often as recommended in the package insert [27]. A long-acting formulation of diclofenac has been developed, and future results are expected to show whether it improves adherence. Further studies are also needed to achieve good adherence.

Eye drops expected to be approved for the treatment of DED in Asia include tacrolimus ophthalmic solution [101][102], tanfenercept ophthalmic solution [103], lifitegrast ophthalmic solution [104], perfluorohexyloctane ophthalmic solution [105], and lactoferrin ophthalmic solution [106]. Adjunctive therapies that are as promising as eye drops include vectored thermal pulsation system [107], intraductal meibomian gland probing [108], and contact lens drug delivery system [109]. It is hoped that results will be reported from Asia in randomized controlled trials in these eye drops and treatments.

#### 5. Literature Search

A literature search was conducted using PubMed on October 9, 2022 to systematically search for randomized controlled and non-randomized trials of treatments for DED. The titles and abstracts of the retrieved articles were read to identify full-text original articles in English on human subjects published from Asia in 2021 or 2022, and new findings in those articles were identified to determine which treatments to review in this article. I also included in the selection criteria papers in

press that the the author was involved in and accepted for publication in 2022. Papers that were available only as review articles, abstracts or conference posters, and those that were not available in English were excluded.

---

**Acknowledgements:** I would like to thank Shin-ichiro Yoshida for his contribution.

**Conflicts of Interest:** The author declares no conflict of interest.

**Funding:** This research received no funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

## References

- <sup>^</sup> Nakamura, M.; Mishima, H.; Nishida, T.; Otori, T. Binding of hyaluronan to plasma fibronectin increases the attachment of corneal epithelial cells to a fibronectin matrix. *J. Cell. Physiol.* 1994, 159, 415-422.
- <sup>^</sup> Nakamura, M.; Nishida, T.; Hikida, M.; Otori, T. Combined effects of hyaluronan and fibronectin on corneal epithelial wound closure of rabbit in vivo. *Curr. Eye. Res.* 1994, 13, 385–388.
- <sup>^</sup> Nakamura, M.; Hikida, M.; Nakano, T.; Ito, S.; Hamano, T.; Kinoshita S. Characterization of water retentive properties of hyaluronan. *Cornea.* 1993, 12, 433-436.
- <sup>^</sup> Asari, A.; Kanemitsu, T.; Kurihara, H. Oral administration of high molecular weight hyaluronan (900 kDa) controls immune system via Toll-like receptor 4 in the intestinal epithelium. *J. Biol. Chem.* 2010, 285, 24751-24758.
- <sup>^</sup> Greco, R.M.; Iacono, J.A.; Ehrlich, H.P. Hyaluronic acid stimulates human fibroblast proliferation within a collagen matrix. *Journal of Cellular Physiology.* 1998, 177, 465-473.
- <sup>^</sup> Kim, Y.; Moon, C.H.; Kim, B.Y.; Jang, S.Y. Oral Hyaluronic Acid Supplementation for the Treatment of Dry Eye Disease: A Pilot Study. *J. Ophthalmol.* 2019, 2019, 5491626.
- <sup>^</sup> Uchino, M.; Yokoi, N.; Uchino, Y.; Dogru, M.; Kawashima, M.; Komuro, A.; Sonomura, Y.; Hiroaki Kato, H.; Kinoshita, S.; Schaumberg, D.A.; Tsubota, K. Dry eye disease and work productivity loss in visual display users: the Osaka study. *Am. J. Ophthalmol.* 2014, 157, 294-300.
- <sup>a, b, c</sup> Tsubota, K.; Yokoi, N.; Shimazaki, J.; Watanabe, H.; Dogru, M.; Yamada, M.; Kinoshita, S.; Kim, H.M.; Tchah, H.W.; Hyon, J.Y.; Yoon, K.C.; Seo, K.Y.; Sun, X.; Chen, W.; Liang, L.; Li, M.; Liu, Z.; Asia Dry Eye Society. *New Perspectives on Dry Eye Definition and Diagnosis: A Consensus Report by the Asia Dry Eye Society.* *Ocul. Surf.* 2017,



15, 65-76.

9. <sup>^</sup>Labetoulle, M.; Benitez-Del-Castillo, J.M.; Barabino, S.; Herrero Vanrell, R.; Daull, P.; Garrigue, J.S.; Rolando, M. *Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease*. *Int. J. Mol. Sci.* 2022, 23, 2434.
10. <sup>^</sup>Coco, G.; Iannetta, D.; Febbraro, I.; Elmo, E.; Manni, G. *Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study*. *J. Ophthalmol.* 2022, 2022, 1320996.
11. <sup>^</sup>von K ugelgen, I. *Molecular pharmacology of P2Y receptor subtypes*. *Biochem. Pharmacol.* 2021, 187, 114361.
12. <sup>^</sup>Tanioka, H.; Kuriki, Y.; Sakamoto, A.; Katsuta, O.; Kawazu, K.; Nakamura, M. *Expression of the P2Y<sub>2</sub> receptor on the rat ocular surface during a 1-year rearing period*. *Jpn. J. Ophthalmol.* 2014, 58, 515-521.
13. <sup>^</sup>Terakado, K.; Yogo, T.; Kohara, Y.; Soeta, S.; Nezu, Y.; Harada, Y.; Hara, Y.; Amasaki, H.; Tagawa, M. *Conjunctival expression of the P2Y<sub>2</sub> receptor and the effects of 3% diquafosol ophthalmic solution in dogs*. *Vet. J.* 2014, 202, 48-52.
14. <sup>^</sup>Hori, Y.; Kageyama, T.; Sakamoto, A.; Shiba, T.; Nakamura, M.; Maeno, T. *Comparison of Short-Term Effects of Diquafosol and Rebamipide on Mucin 5AC Level on the Rabbit Ocular Surface*. *J. Ocul. Pharmacol. Ther.* 2017, 33, 493-497.
15. <sup>a, b, c</sup>Yokoi, N.; Kato, H.; Kinoshita, S. *Facilitation of tear fluid secretion by 3% diquafosol ophthalmic solution in normal human eyes*. *Am. J. Ophthalmol.* 2014, 157, 85-92.e1.
16. <sup>^</sup>Miyake, H.; Kawano, Y.; Tanaka, H.; Iwata, A.; Imanaka, T.; Nakamura, M. *Tear volume estimation using a modified Schirmer test: a randomized, multicenter, double-blind trial comparing 3% diquafosol ophthalmic solution and artificial tears in dry eye patients*. *Clin. Ophthalmol.* 2016, 10, 879-886.
17. <sup>^</sup>Li, Y.; Kuang, K.; Yerxa, B.; Wen, Q.; Rosskothien, H.; Fischbarg, J. *Rabbit conjunctival epithelium transports fluid, and P2Y<sub>2</sub>(2) receptor agonists stimulate Cl(-) and fluid secretion*. *Am. J. Physiol. Cell. Physiol.* 2001, 281, C595-602.
18. <sup>^</sup>Fukuoka, S.; Arita, R. *Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction: a randomized clinical study*. *Sci. Rep.* 2019, 9, 9091.
19. <sup>^</sup>Zhang, Q.; Zhang, H.; Qin, G.; Wu, Y.; Song, Y.; Yang, L.; Yu, S.; He, X.; Moore, J.E.; Moutari, S.; Palme, C.; Xu, L.; He, W.; Pazo, E.E. *Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye: A Pilot Study*. *J. Ocul. Pharmacol. Ther.* 2022, 38, 133-140.
20. <sup>^</sup>Yokoi, N.; Sonomura, Y.; Kato, H.; Komuro, A.; Kinoshita, S. *Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sj gren's syndrome*. *Eye (Lond)*. 2015, 29, 1204-1212.
21. <sup>^</sup>Fukuoka, S.; Arita, R. *Increase in tear film lipid layer thickness after instillation of 3% diquafosol ophthalmic solution in healthy human eyes*. *Ocul. Surf.* 2017, 15, 730-735.
22. <sup>^</sup>Byun, Y.S.; Yoo, Y.S.; Kwon, J.Y.; Joo, J.S.; Lim, S.A.; Whang, W.J.; Mok, J.W.; Choi, J.S.; Joo, C.K. *Diquafosol promotes corneal epithelial healing via intracellular calcium-mediated ERK activation*. *Exp. Eye. Res.* 2016, 143, 89-97.
23. <sup>^</sup>Park, J.H.; Moon, S.H.; Kang, D.H.; Um, H.J.; Kang, S.S.; Kim, J.Y.; Tchah, H. *Diquafosol Sodium Inhibits Apoptosis*

- and Inflammation of Corneal Epithelial Cells Via Activation of Erk1/2 and RSK: In Vitro and In Vivo Dry Eye Model. *Invest. Ophthalmol. Vis. Sci.* 2018, 59, 5108-5115.
24. <sup>a, b</sup>Wu, D.; Chen, W.Q.; Li, R.; Wang, Y. Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: a systematic review of randomized clinical trials. *Cornea.* 2015, 34, 644-650.
25. <sup>^</sup>Miljanovic, B.; Dana, R.; Sullivan, D.A.; Schaumberg, D.A. Impact of dry eye syndrome on vision-related quality of life. *Am. J. Ophthalmol.* 2007, 143, 409-415.
26. <sup>^</sup>Matsumoto, Y.; Ohashi, Y.; Watanabe, H.; Tsubota, K. Diquafosol Ophthalmic Solution Phase 2 Study Group Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome a Japanese phase 2 clinical trial. *Ophthalmology.* 2012, 119, 1954-1960.
27. <sup>a, b</sup>Uchino, M.; Yokoi, N.; Shimazaki, J.; Hori, Y.; Tsubota, K. On Behalf Of The Japan Dry Eye Society. Adherence to eye drops usage in dry eye patients and reasons for non-compliance: a web-based survey. *J. Clin. Med.* 2022, 11, 367.
28. <sup>a, b</sup>Hori, Y.; Oka, K.; Inai, M. Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study. *Adv. Ther.* 2022, 39, 3654-3667.
29. <sup>a, b</sup>Kinoshita, S.; Oshiden, K.; Awamura, S.; Suzuki, H.; Nakamichi, N.; Yokoi, N.; Rebamipide Ophthalmic Suspension Phase 3 Study Group. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. *Ophthalmology.* 2013, 120, 1158-1165.
30. <sup>^</sup>Urashima, H.; Okamoto, T.; Takeji, Y.; Shinohara, H.; Fujisawa, S. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. *Cornea.* 2004, 23, 613-619.
31. <sup>^</sup>Yamasaki, K.; Kanbe, T.; Chijiwa, T.; Ishiyama, H.; Morita, S. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. *Eur. J. Pharmacol.* 1987, 142, 23-29.
32. <sup>^</sup>Kimura, K.; Morita, Y.; Orita, T.; Haruta, J.; Takeji, Y.; Sonoda, K.H. Protection of human corneal epithelial cells from TNF- $\alpha$ -induced disruption of barrier function by rebamipide. *Invest. Ophthalmol. Vis. Sci.* 2013, 54, 2572-2760.
33. <sup>a, b</sup>Koh, S.; Maeda, N.; Hori, Y.; Inoue, T.; Watanabe, H.; Hirohara, Y.; Mihashi, T.; Fujikado, T.; Tano, Y. Effects of suppression of blinking on quality of vision in borderline cases of evaporative dry eye. *Cornea.* 2008, 27, 275-278.
34. <sup>^</sup>Kinoshita, S.; Awamura, S.; Nakamichi, N.; Suzuki, H.; Oshiden, K.; Yokoi, N.; Rebamipide Ophthalmic Suspension Long-term Study Group. A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye. *Am. J. Ophthalmol.* 2014, 157, 576-583.
35. <sup>^</sup>Kinoshita, S.; Awamura, S.; Oshiden, K.; Nakamichi, N.; Suzuki, H.; Yokoi, N. Rebamipide (OPC-12759) in the treatment of dry eye a randomized, doublemasked, multicenter, placebo-controlled phase II study. *Ophthalmology.* 2012, 119, 2471-2478.
36. <sup>^</sup>Teshigawara, T.; Meguro, A.; Mizuki, N. Impact of Perioperative Dry Eye Treatment with Rebamipide Versus Artificial Tears on Visual Outcomes After Cataract Surgery in Japanese Population. *Ophthalmol. Ther.* 2022, 11, 1479-1491.
37. <sup>^</sup>Stern, M.E.; Pflugfelder, S.C. Inflammation in dry eye. *Ocul. Surf.* 2004, 2, 124-130.
38. <sup>^</sup>Chauhan, S.K.; El-Annan, J.; Ecoiffier, T.; Goyal, S.; Zhang, Q.; Saban, D.R.; Dana, R. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. *J. Immunol.* 2009, 182, 1247-1252.
39. <sup>^</sup>De, Paiva, C.S.; Chotikavanich, S.; Pangelinan, S.B.; Pitcher, J.D. 3rd.; Fang, B.; Zheng, X.; Ma, P.; Farley, W.J.;

- Siemasko, K.F.; Niederkorn, J.Y.; Stern, M.E.; Li, D.Q.; Pflugfelder, S.C. IL-17 disrupts corneal barrier following desiccating stress. *Mucosal. Immunol.* 2009, 2, 243-253.
40. ^ Lee SY, Han SJ, Nam SM, Yoon SC, Ahn JM, Kim TI, Kim EK, Seo KY. Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non-Sjögren syndrome dry eye patients. *Am. J. Ophthalmol.* 2013, 156, 247-253.e1.
41. ^ Lemp, M.A. The mucin-deficient dry eye. *Int. Ophthalmol. Clin.* 1973, 13, 185-189.
42. ^ Rivas, L.; Lopez-Garcia, J.S.; Murube, J.; Garcia-Lozano, I. Different conjunctival adaptive response in patients with aqueous-deficient and with mucous-deficient dry eyes. *Eur. J. Ophthalmol.* 2007, 17, 160-170.
43. ^ Tuan, H.I.; Chi, S.C.; Kang, Y.N. An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease. *Drug. Des. Devel. Ther.* 2020, 14, 265-274.
44. ^ Pflugfelder, S.C.; De, Paiva, C.S.; Villarreal, A.L.; Stern, M.E. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. *Cornea.* 2008, 27, 64-69.
45. ^ Stonecipher, K.G.; Torkildsen, G.L.; Ousler, G.W.; Morris, S.; Villanueva, L.; Hollander, D. The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye. *Clinical. Ophthalmology.* 2016, 10, 887–895.
46. ^ Perry, H.D.; Solomon, R.; Donnenfeld, E.D.; Perry, A.R.; Wittpenn, J.R.; Greenman, H.E.; Savage, H.E. Evaluation of topical cyclosporine for the treatment of dry eye disease. *Arch. Ophthalmol.* 2008, 126, 1046-1050.
47. ^ Hoy, S.M. Cyclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease. *Drugs.* 2017, 77, 1909-1916.
48. ^ Eom, Y.; Song, J.S.; Kim, H.M. Effectiveness of Topical Cyclosporin A 0.1%, Diquafosol Tetrasodium 3%, and Their Combination, in Dry Eye Disease. *J. Ocul. Pharmacol. Ther.* 2022, 38, 682-694.
49. ^ Capita, L.; Chalita, M.R.; dos Santos-Neto, L.L. Prospective evaluation of hypromellose 2% for punctal occlusion in patients with dry eye. *Cornea.* 2015, 34, 188-192.
50. <sup>a, b</sup> Guzey, M.; Ozardali, I.; Kilic, A.; Basar, E.; Dogan, Z.; Satici, A.; Karadede, S. The treatment of severe trachomatous dry eye with canalicular silicone plugs. *Eye (Lond).* 2001, 15, 297-303.
51. ^ Nava-Castaneda, A.; Tovilla-Canales, J.L.; Rodriguez, L.; Tovilla-y-Pomar, J.L.; Jones, C.E. Effects of lacrimal occlusion with collagen and silicone plugs on patients with conjunctivitis associated with dry eye. *Cornea.* 2003, 22, 10-14.
52. ^ Roberts, C.W.; Carniglia, P.E.; Brazzo, B.G. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. *Cornea.* 2007, 26, 805-809.
53. ^ Liu, Q.; Liu, J.; Ren, C.; Cai, W.; Wei, Q.; Song, Y.; Yu, J. Proteomic analysis of tears following acupuncture treatment for menopausal dry eye disease by two-dimensional nano-liquid chromatography coupled with tandem mass spectrometry. *Int. J. Nanomedicine.* 2017, 12, 1663-1671.
54. ^ Liu, Z.; Jin, M.; Li, Y.; Liu, J.; Xiao, X.; Bi, H.; Pan, Z.; Shi, H.; Xie, X.; Zhang, M.; Gao, X.; Li, L.; Ouyang, W.; Tang, L.; Wu, J.; Yang, Y.; Hu, J.; Liu, Z. Efficacy and Safety of Houltuynia Eye Drops Atomization Treatment for Meibomian Gland Dysfunction-Related Dry Eye Disease: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. *J. Clin. Med.* 2020, 9, 4022.

55. <sup>^</sup>Lan W, Tong L. Acupuncture has effect on increasing tear break-up time: acupuncture for treating dry eye, a randomized placebo-controlled trial. *Acta. Ophthalmol.* 2012, 90, e73.
56. <sup>^</sup>Gong, L.; Sun, X.; Chapin, W.J. Clinical curative effect of acupuncture therapy on xerophthalmia. *Am. J. Chin. Med.* 2010, 38, 651-659.
57. <sup>^</sup>Bäcker, M.; Grossman, P.; Schneider, J.; Michalsen, A.; Knoblauch, N.; Tan, L.; Niggemeyer, C.; Linde, K.; Melchart, D.; Dobos, G.J. Acupuncture in migraine: investigation of autonomic effects. *Clin. J. Pain.* 2008, 24, 106-115.
58. <sup>^</sup>Gong L, Sun X. Treatment of intractable dry eyes: tear secretion increase and morphological changes of the lacrimal gland of rabbit after acupuncture. *Acupunct. Electrother. Res.* 2007, 32, 223-233.
59. <sup>a, b</sup>Hu, W.L.; Yu, H.J.; Pan, L.Y.; Wu, P.C.; Pan, C.C.; Kuo, C.E.; Tseng, Y.J.; Hung, Y.C. Laser Acupuncture Improves Tear Film Stability in Patients with Dry Eye Disease: A Two-Center Randomized-Controlled Trial. *J. Altern. Complement. Med.* 2021, 27, 579-587.
60. <sup>^</sup>Qin, H.Y.; Peng, Q.H. Study on the mechanism of acupuncture treatment of dry eye. *Guiding. J. Tradit. Chin. Med. Pharm.* 2019, 25, 116–119.
61. <sup>^</sup>Stellon, A. The use of laser acupuncture for the treatment of neurogenic pruritus in a child—A case history. *Acupunct. Med.* 2005, 23, 31–33.
62. <sup>^</sup>Whittaker, P. Laser acupuncture: Past, present, and future. *Lasers. Med. Sci.* 2004, 19, 69–80.
63. <sup>^</sup>Haedersdal, M.; Beerwerth, F.; Nash, J.F. Laser and intense pulsed light hair removal technologies: from professional to home use. *Br. J. Dermatol.* 2011, 165 Suppl 3, 31-36.
64. <sup>^</sup>Goldman, M.P.; Weiss, R.A.; Weiss, M.A. Intense pulsed light as a nonablative approach to photoaging. *Dermatol. Surg.* 2005, 31(9 Pt 2), 1179-1187; discussion 1187.
65. <sup>^</sup>Li, Y.H.; Wu, Y.; Chen, J.Z.; Gao, X.H.; Liu, M.; Shu, C.M.; Dong, G.H.; Chen, H.D. Application of a new intense pulsed light device in the treatment of photoaging skin in Asian patients. *Dermatol Surg.* 2008, 34, 1459-1464.
66. <sup>^</sup>Negishi, K.; Tezuka, Y.; Kushikata, N.; Wakamatsu, S. Photorejuvenation for Asian skin by intense pulsed light. *Dermatol. Surg.* 2001, 27, 627-631; discussion 632.
67. <sup>^</sup>Goldberg, D.J. Current trends in intense pulsed light. *J. Clin. Aesthet. Dermatol.* 2012, 5, 45-53.
68. <sup>^</sup>Wat, H.; Wu, D.C.; Rao, J.; Goldman, M.P. Application of intense pulsed light in the treatment of dermatologic disease: a systematic review. *Dermatol. Surg.* 2014, 40, 359-377.
69. <sup>^</sup>Toyos, R. Intense pulsed light for dry eye syndrome. *Cataract and Refractive Surgery Today.* 2009, April, 71–73.
70. <sup>^</sup>Jiang, X.; Lv, H.; Song, H.; Zhang, M.; Liu, Y.; Hu, X.; Li, X.; Wang, W. Evaluation of the Safety and Effectiveness of Intense Pulsed Light in the Treatment of Meibomian Gland Dysfunction. *J. Ophthalmol.* 2016, 2016, 1910694.
71. <sup>^</sup>Liu, R.; Rong, B.; Tu, P.; Tang, Y.; Song, W.; Toyos, R.; Toyos, M.; Yan, X. Analysis of Cytokine Levels in Tears and Clinical Correlations After Intense Pulsed Light Treating Meibomian Gland Dysfunction. *Am. J. Ophthalmol.* 2017, 183, 81-90.
72. <sup>a, b</sup>Choi, M.; Han, S.J.; Ji, Y.W.; Choi, Y.J.; Jun, I.; Alotaibi, M.H.; Ko, B.Y.; Kim, E.K.; Kim, T.I.; Nam, S.M.; Seo, K.Y. Meibum Expressibility Improvement as a Therapeutic Target of Intense Pulsed Light Treatment in Meibomian Gland Dysfunction and Its Association with Tear Inflammatory Cytokines. *Sci. Rep.* 2019, 9, 7648.
73. <sup>^</sup>Piyacomn Y, Kasetsuwan N, Reinprayoon U, Satiitpitakul V, Tesapirat L. Efficacy and Safety of Intense Pulsed Light in

- Patients With Meibomian Gland Dysfunction-A Randomized, Double-Masked, Sham-Controlled Clinical Trial. Cornea. 2020, 39, 325-332.*
74. <sup>^</sup>Xue, A.L.; Wang, M.T.M.; Ormonde, S.E.; Craig, J.P. Randomised double-masked placebo-controlled trial of the cumulative treatment efficacy profile of intense pulsed light therapy for meibomian gland dysfunction. *Ocul. Surf.* 2020, 18, 286-297.
75. <sup>^</sup>Arita, R.; Mizoguchi, T.; Fukuoka, S.; Morishige, N. Multicenter Study of Intense Pulsed Light Therapy for Patients With Refractory Meibomian Gland Dysfunction. *Cornea.* 2019, 38, e4.
76. <sup>^</sup>Arita, R.; Fukuoka, S.; Morishige, N. Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. *Ocul. Surf.* 2019, 17, 104–110.
77. <sup>^</sup>Piccolo, D.; Di, Marcantonio, D.; Crisman, G.; Cannarozzo, G.; Sannino, M.; Chiricozzi, A.; Chimenti, S. Unconventional use of intense pulsed light. *Biomed Res Int.* 2014, 2014, 618206.
78. <sup>^</sup>Jiang, X.; Yuan, H.; Zhang, M.; Lv, H.; Chou, Y.; Yang, J.; Li, X. The Efficacy and Safety of New-Generation Intense Pulsed Light in the Treatment of Meibomian Gland Dysfunction-Related Dry Eye: A Multicenter, Randomized, Patients-Blind, Parallel-Control, Non-Inferiority Clinical Trial. *Ophthalmol. Ther.* 2022, 11, 1895-1912.
79. <sup>^</sup>Epstein, I.J.; Rosenberg, E.; Stuber, R.; Choi, M.B.; Donnenfeld, E.D.; Perry, H.D. Double-masked and unmasked prospective study of terpinen-4-ol lid scrubs with microblepharoexfoliation for the treatment of demodex blepharitis. *Cornea.* 2020, 39, 408-416.
80. <sup>^</sup>Rynerson, J.M.; Perry, H.D. DEBS - a unification theory for dry eye and blepharitis. *Clin. Ophthalmol.* 2016, 10, 2455-2467.
81. <sup>^</sup>Dong, X.; Wang, Y.; Wang, W.; Lin, P.; Huang, Y. Composition and diversity of bacterial community on the ocular surface of patients with meibomian gland dysfunction. *Invest. Ophthalmol. Vis. Sci.* 2019, 60, 4774-4783.
82. <sup>^</sup>Mireille, Aye, A.; Bonnin-Jusserand, M.; Brian-Jaisson, F.; Ortalo-Magne, A.; Culioli, G.; Koffi, Nevry, R.; Rabah, N.; Blache, Y.; Molmeret, M. Modulation of violacein production and phenotypes associated with biofilm by exogenous quorum sensing N-acylhomoserine lactones in the marine bacterium *Pseudoalteromonas ulvae* TC14. *Microbiology.* 2015, 161, 2039-2051.
83. <sup>^</sup>Hastings, J.W.; Greenberg, E.P. Quorum sensing: the explanation of a curious phenomenon reveals a common characteristic of bacteria. *J. Bacteriol.* 1999, 181, 2667-2668.
84. <sup>^</sup>Yarwood, J.M.; Schlievert, P.M. Quorum sensing in *Staphylococcus* infections. *J. Clin. Invest.* 2003, 112, 1620-1625.
85. <sup>^</sup>Moon, S.Y.; Han, S.A.; Kwon, H.J.; Park, S.Y.; Lee, J.H.; Chung, H.S.; Kim, J.Y.; Tchah, H.; Lee, H. Effects of lid debris debridement combined with meibomian gland expression on the ocular surface MMP-9 levels and clinical outcomes in moderate and severe meibomian gland dysfunction. *BMC. Ophthalmol.* 2021, 21, 175.
86. <sup>^</sup>Tsubota, K.; Goto, E.; Fujita, H. Treatment of dry eye by autologous serum application in Sjogren's syndrome. *Br. J. Ophthalmol.* 1999, 83, 390–395.
87. <sup>^</sup>Rocha, E.M.; Pelegrino, F.S.; de Paiva, C.S.; Vigorito, A.C.; de Souza, C.A. GVHD dry eyes treated with autologous serum tears. *Bone. Marrow. Transplant.* 2000, 25, 1101-1103.
88. <sup>^</sup>del Castillo, J.M.; de la Casa, J.M.; Sardiña, R.C.; Fernández, R.M.; Feijoo, J.G.; Gómez, A.C.; Rodero, M.M.; Sánchez, J.G. Treatment of recurrent corneal erosions using autologous serum. *Cornea.* 2002, 21, 781-783.

89. ^Young, A.L.; Cheng, A.C.; Ng, H.K.; Cheng, L.L.; Leung, G.Y.; Lam, D.S. *The use of autologous serum tears in persistent corneal epithelial defects.* *Eye (Lond).* 2004, 18, 609-614.
90. ^Matsumoto, Y.; Dogru, M.; Goto, E.; Ohashi, Y.; Kojima, T.; Ishida, R.; Tsubota K. *Autologous serum application in the treatment of neurotrophic keratopathy.* *Ophthalmology.* 2004, 111, 1115-1120.
91. <sup>a, b</sup>Sharma, N.; Goel, M.; Velpandian, T.; Titiyal, J.S.; Tandon, R.; Vajpayee, R.B. *Evaluation of umbilical cord serum therapy in acute ocular chemical burns.* *Invest. Ophthalmol. Vis. Sci.* 2011, 52, 1087-1092.
92. ^Vajpayee, R.B.; Mukerji, N.; Tandon, R.; Sharma, N.; Pandey, R.M.; Biswas, N.R.; Malhotra, N.; Melki, S.A. *Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects.* *Br. J. Ophthalmol.* 2003, 87, 1312-1316.
93. ^Yoon, K.C.; You, I.C.; Im, S.K.; Jeong, T.S.; Park, Y.G.; Choi, J. *Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis.* *Ophthalmology.* 2007, 114, 1637-1642.
94. ^Yoon, K.C.; Jeong, I.Y.; Im, S.K.; Park, Y.G.; Kim, H.J.; Choi, J. *Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease.* *Bone Marrow Transplant.* 2007, 39, 231-235.
95. ^Yoon, K.C.; Im, S.K.; Park, Y.G.; Jung, Y.D.; Yang, S.Y.; Choi, J. *Application of umbilical cord serum eyedrops for the treatment of dry eye syndrome.* *Cornea.* 2006, 25, 268-272.
96. ^Yoon, K.C.; Heo, H.; Jeong, I.Y.; Park, Y.G. *Therapeutic effect of umbilical cord serum eyedrops for persistent corneal epithelial defect.* *Korean J. Ophthalmol.* 2005, 19, 174-178.
97. ^Tsubota, K.; Higuchi, A. *Serum application for the treatment of ocular surface disorders.* *Int. Ophthalmol. Clin.* 2000, 40, 113-122.
98. ^Kumar, A.; Kumar, K.; Kubrey, S.; Chaurasiya, D.; Sultan, S.; Karkhur, S.; Soni, D.; Mohan, R.R.; Sharma, B. *Therapeutic profile of human umbilical cord blood serum and autologous serum therapies in treatment of ocular surface disorders- A pilot study.* *J. Ocul. Pharmacol. Ther.* in press.
99. ^Urzua, C.A.; Vasquez, D.H.; Huidobro, A.; Hernandez, H.; Alfaro, J. *Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome.* *Curr. Eye. Res.* 2012, 37, 684-688.
100. ^Celebi, A.R.; Ulusoy, C.; Mirza, G.E. *The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study.* *Graefes. Arch. Clin. Exp. Ophthalmol.* 2014, 252, 619-626.
101. ^Moawad, P.; Shamma, R.; Hassanein, D.; Ragab, G.; El Zawahry, O. *Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome.* *Eur. J. Ophthalmol.* 2022, 32, 673-679.
102. ^Mohammad; Garg, V.; Nirmal, J.; Warsi, M.H.; Pandita, D.; Kesharwani, P.; Jain, G.K. *Topical Tacrolimus Proglycosomes Nano-Vesicles As a Potential Therapy for Experimental Dry Eye Syndrome.* *J. Pharm. Sci.* 2022, 111, 479-484.
103. ^Dong, Y.; Wang, S.; Cong, L.; Zhang, T.; Cheng, J.; Yang, N.; Qu, X.; Li, D.; Zhou, X.; Wang, H.; Lee, M.; Wang, M.; Chen, S.; Ousler, G.W.; Chen, X.; Xie, L. *TNF- $\alpha$  inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China.* *Int. Ophthalmol.* 2022, 42, 2459-2472.
104. ^Li, J.X.; Tsai, Y.Y.; Lai, C.T.; Li, Y.L.; Wu, Y.H.; Chiang, C.C. *Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.* *J. Clin. Med.* 2022, 11, 5014.

105. <sup>^</sup>Delicado-Miralles, M.; Velasco, E.; Díaz-Tahoces, A.; Gallar, J.; Acosta, M.C.; Aracil-Marco A. *Deciphering the Action of Perfluorohexyloctane Eye Drops to Reduce Ocular Discomfort and Pain. Front. Med. (Lausanne). 2021, 8, 709712.*
106. <sup>^</sup>Vagge, A.; Senni, C.; Bernabei, F.; Pellegrini, M.; Scordia, V.; Traverso, C.E.; Giannaccare, G. *Therapeutic Effects of Lactoferrin in Ocular Diseases: From Dry Eye Disease to Infections. Int J Mol Sci. 2020, 21, 6668.*
107. <sup>^</sup>Hu, J.; Zhu, S.; Liu, X. *Efficacy and safety of a vectored thermal pulsation system (Lipiflow®) in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis. Graefes. Arch. Clin. Exp. Ophthalmol. 2022, 260, 25-39.*
108. <sup>^</sup>Magno, M.; Moschowits, E.; Arita, R.; Vehof, J.; Utheim, T.P. *Intraductal meibomian gland probing and its efficacy in the treatment of meibomian gland dysfunction. Surv. Ophthalmol. 2021, 66, 612-622.*
109. <sup>^</sup>Guzman-Aranguez, A.; Fonseca, B.; Carracedo, G.; Martin-Gil, A.; Martinez-Aguila, A.; Pintor, J. *Dry Eye Treatment Based on Contact Lens Drug Delivery: A Review. Eye. Contact. Lens. 2016, 42, 280-288.*